Compound Radar

10x Genomics, Inc. (TXG) Stock Analysis

United States · Healthcare / Medical Devices

Price $65.60
Market cap $8.55B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

66
66/100 Good Quality
  • Financial Health 70
  • Profitability 40
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 80

Why this rating?

Health 66/100 — Good Quality

Strongest Cash Flow 80/100
Softest Profitability 40/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

10x Genomics, Inc. (TXG) is a Medical Devices company in the Healthcare sector. Compound Radar rates 10x Genomics, Inc. 66/100 (Good Quality) due to high business quality.

Investment profile

  • Quality High
  • Growth Soft
  • Balance Sheet Unknown
  • Valuation Elevated

Financial highlights

Valuation

  • Forward P/E 322.63
  • EV/Revenue 12.47

Profitability

  • Revenue Growth -12.7%
  • Gross Margin 70.1%
  • Operating Margin -15.2%
  • Net Margin -12.2%
  • ROE -9.4%

Financial strength

  • Cash $552.03M
  • Debt $78.80M
  • Net Cash $473.24M
  • Free Cash Flow $130.12M
  • Current Ratio 5.69

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks 10x Genomics, Inc. (TXG).

View Methodology & FAQ →